國立虎尾科技大學 |

Chronic Myeloid Leukemia

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Chronic Myeloid Leukemia/ edited by Rüdiger Hehlmann.
其他作者:	Hehlmann, Rüdiger.
面頁冊數:	X, 255 p. 40 illus., 39 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Hematology. -
電子資源:	https://doi.org/10.1007/978-3-319-33198-0
ISBN:	9783319331980

Chronic Myeloid Leukemia
Chronic Myeloid Leukemia[electronic resource] /edited by Rüdiger Hehlmann. - 1st ed. 2016. - X, 255 p. 40 illus., 39 illus. in color.online resource. - Hematologic Malignancies,2197-9766. - Hematologic Malignancies,.

Cytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML‐treatment -- A review and up‐date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP‐competitive BCR‐ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response‐related predictors of survival -- CML‐ blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon‐alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. .

ISBN: 9783319331980

Standard No.: 10.1007/978-3-319-33198-0doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Chronic Myeloid Leukemia
LDR:03397nam a22004095i 4500 001 977245
003 DE-He213
005 20200630003049.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319331980 $9 978-3-319-33198-0
024 7 $a 10.1007/978-3-319-33198-0 $2 doi
035 $a 978-3-319-33198-0
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Chronic Myeloid Leukemia $h [electronic resource] / $c edited by Rüdiger Hehlmann.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a X, 255 p. 40 illus., 39 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Hematologic Malignancies, $x 2197-9766
505 0 $a Cytogenetics of CML -- The biology and pathogenesis of CML -- The choice of 1st line CML‐treatment -- A review and up‐date of the European LeukemiaNet recommendations for the management of CML -- Management of adverse events associated with ATP‐competitive BCR‐ABL 1 tyrosine kinase inhibitors in CML -- Standardization of molecular monitoring for CML -- Epidemiology of CML -- Prognostic scores for patients with CML under particular consideration of disease specific death -- Response‐related predictors of survival -- CML‐ blast crisis: implications and management -- Chronic Myeloid Leukemia and Pregnancy -- The role of hematopoietic stem cell transplantation in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in CML patients with deep molecular response -- The interferon‐alpha revival in CML -- Changing the cost of care for CML: the availability of generic imatinib.
520 $a This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. .
650 0 $a Hematology. $3 645254
700 1 $a Hehlmann, Rüdiger. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1271017
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319331973
776 0 8 $i Printed edition: $z 9783319331997
776 0 8 $i Printed edition: $z 9783319814513
830 0 $a Hematologic Malignancies, $x 2197-9766 $3 1253495
856 4 0 $u https://doi.org/10.1007/978-3-319-33198-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)